Powered by AJICAP™ Site-Specific Conjugation Technology
At the core of our site-specific conjugation services is AJICAP™, our proprietary site-specific antibody conjugation and linker technology, enabling precise payload attachment to native antibodies with defined drug-to-antibody ratio (DAR) control and broad payload compatibility.
Accelerates Early Discovery
- Native IgG antibodies can be used directly without antibody engineering, enabling faster evaluation and reducing development complexity.
- Site-specific chemical conjugation eliminates the need for enzymatic modification, simplifying workflows and supporting cost-effective process development.
- Broad compatibility with antibodies and diverse payloads enables efficient screening, optimization, and scale-up across multiple bioconjugate modalities
Precise, Reproducible Conjugation
- AJICAP™ enables site-specific payload attachment with precise drug-to-antibody ratio (DAR) control, producing highly homogeneous antibody conjugates.
- Defined conjugation sites improve product consistency, reproducibility, and analytical characterization throughout development.
- The platform supports multiple conjugation strategies, including homogeneous DAR1 as well as higher DAR and dual-payload configurations, depending on program requirements
Robust Manufacturing & Payload Compatibility
- Compatible with a wide range of payloads, including cytotoxic small molecules, peptides, oligonucleotides, and nanoparticle conjugates.
- Hydrophilic linker strategies can reduce hydrophobicity, improve plasma stability, and minimize payload detachment during circulation.
- A straightforward chemical conjugation process, without antibody engineering or enzymatic steps, simplifies scale-up and manufacturing while minimizing or avoiding column purification.